The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Abstract
Rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20, was the first monoclonal antibody to be approved for therapeutic use. Treatment with rituximab at standard weekly dosing is effective in more than 50% of patients with relapsed or refractory CD20-positive follicular non-Hodgkin's lymphoma, but is not curative. It is less effective in other subtypes of CD20-positive lymphoma and for retreatment, even with CD20 still expressed. Thus, binding of rituximab to CD20 is not sufficient to kill many lymphoma cells, indicating that there are mechanisms of resistance. Mechanisms of cell destruction that have been demonstrated to be activated by rituximab binding to CD20 include direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity. The relative importance of each of these mechanisms in determining clinical response to rituximab treatment remains a matter of conjecture. Thus, the role of various resistance pathways, some documented in experimental systems and others still hypothetical, remains uncertain. Resistance could potentially be mediated by alterations in CD20 expression or signaling, elevated apoptotic threshold, modulation of complement activity or diminished cellular cytotoxicity. As the first of an expanding class of anticancer agents, lessons learned regarding the mechanism of rituximab action and resistance will be of increasing importance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rituximab is an anti-CD20 mAb that depletes B cells by inducing apoptosis (49).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [49]
In the citing paper
“Rituximab (RTX) is a chimeric mouse/human monoclonal antibody targeting CD20 present in pre‐B and mature B cells except plasma cells.”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [81]
In the citing paper
“It depletes B cells by inducing apoptosis, antibody dependent cell-mediated cytotoxicity and complement dependent cytotoxicity, thereby limiting antibody production and epitope presentation via MHC class II to TH cells (81).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [81]
Citations
Cites
Harris, N., Jaffe, E., Stein, H., Banks, P., Chan, J., Cleary, M., Delsol, G., De Wolf- Peeters, C., Falini, B., & Gatter, K. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,327
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755 · cited 5×
“Rituximab efficacy and scope of clinical resistance Rituximab is approved for use in refractory or relapsed indolent NHL, based on a pivotal trial demonstrating a response rate of over 50% in such patients (McLaughlin et al., 1998).”
BackgroundInfluentialFisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M., Mize, E. M., Glick, J. H., Coltman, C. A., & Miller, T. P. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304083281404 · Cited by 2,149 · cited 1×
“These are potentially curable with combination chemotherapy, but if not cured usually are fatal within 2–3 years (Fisher et al., 1993).”
BackgroundDepletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900 · cited 2×
“In a small group of patients with previously untreated follicular lymphoma who received rituximab, response rates and molecular complete remission rates were higher in 10 of the 49 patients homozygous for the FcgRIIIA with V158, than those who had either one or two copies of FcgRIIIA with F158 (Cartron et al., 2002).”
BackgroundRavetch, J. V., & Lanier, L. L. (2000) · Science · doi:10.1126/science.290.5489.84 · Cited by 1,283 · cited 5×
“The inhibitory FcgRIIB and KIR signal via ITIM domains that are substrates for src-family tyrosine kinases and that in turn activate PIP3 phosphatase (SHIP) for FcgRIIB or tyrosine phosphatase (SHP-1, -2) for KIR (Ravetch and Lanier, 2000).”
BackgroundInfluentialArmitage, J. O., & Weisenburger, D. D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2780 · Cited by 1,251 · cited 1×
“…with cells indistinguishable from chronic lymphocytic leukemia, and marginal zone- or mucosa-associated NHL. Patients with these indolent NHL have a median survival of approximately 10 years (Armitage and Weisenburger, 1998), but the disease is considered incurable with current therapeutic options.”
BackgroundKeating, M. J., Flinn, I., Jain, V., Binet, J.-L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3554 · Cited by 948 · cited 2×
“In CLL, a disease in which the cells have low CD20 levels and a low response rate to standard dose and schedule rituximab (375mg/m2 weekly 4), higher and repeated doses did lead to higher response rates, although these tend to be short lived (Byrd et al., 2001; Keating et al., 2002b).”
Background
Research works printed but not linked: 1
- Witzig TE, Flinn IW, Gordon LI, Emmanouilldes C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS and White CA . (2002b). J. Clin. Oncol., 20, 2453–2463. · DOI · Paper page
Cited by
Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Fermé, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.131 · Cited by 1,486
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M., Cha, A. C., Chan, C. K., Tan, B. T., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.044 · Cited by 1,087
Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M., & Tedder, T. F. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040119 · Cited by 642
Lenz, G., Dreyling, M., Hoster, E., Wörmann, B., Dührsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.133 · Cited by 574
Metadata
- Authors
- Smith, M. R.
- Affiliations
- Fox Chase Cancer Center (US)
- Corresponding author
- Smith, Mitchell R
- ORCID
- Smith, Mitchell R
- Venue
- Oncogene
- Published
- 2003-10-20
- Volume
- 22
- Issue
- 47
- Pages
- 7359-7368
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2088332148
- Cited by
- 835
- References
- 62
- Citations by year
- 2026: 30 · 2025: 45 · 2024: 33 · 2023: 37 · 2022: 49 · 2021: 64 · 2020: 33 · 2019: 37 · 2018: 32 · 2017: 36 · 2016: 33 · 2015: 35 · 2014: 28 · 2013: 32 · 2012: 31
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- rituximab, CD20, monoclonal antibodies, follicular non-Hodgkin's lymphoma, drug resistance, apoptosis signaling, complement activation, cell-mediated cytotoxicity, CD20 expression, B-cell lymphoma, mechanism of action
- MeSH terms
- Rituximab, Antibodies, Monoclonal, Antigen-Antibody Reactions, Humans, Radioimmunotherapy, Treatment Outcome, Apoptosis, Antigens, CD20, Drug Resistance, Neoplasm, Antibodies, Monoclonal, Murine-Derived
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. https://app.cochat.ai/papers/10.1038/sj.onc.1206939
- The paper
- Smith, M. R. (2003). Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. https://doi.org/10.1038/sj.onc.1206939
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.